Jump to content

Michelle Monje

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 07:14, 9 January 2021 (Add: pmid, s2cid. | You can use this bot yourself. Report bugs here. | Suggested by Abductive | Category:Vassar College alumni‎ | via #UCB_Category 110/735). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Michelle Monje
Michelle Monje, discusses pediatric brain cancer treatments in a video for the National Institute of Neurological Disorders and Stroke in 2015
Born
San Francisco Bay Area
Alma materVassar College
Stanford University
Known forDiffuse Intrinsic Pontine Glioma
Scientific career
InstitutionsStanford University
Doctoral advisorPhilip A. Beachy
Other academic advisorsTheo Palmer

Michelle Leigh Monje-Deisseroth is an associate professor of Neurology at Stanford University. She develops new treatments for Diffuse Intrinsic Pontine Glioma.

Early life and education

Monje wanted to be a physician from the age of five, when she was in kindergarten.[1] She grew up in the San Francisco Bay Area and became interested in biology as a child.[2] Monje was a figure skater during her childhood and taught figure skating to children with developmental disabilities whilst in Junior High.[2] She was an undergraduate student at Vassar College.[2] Monje studied medicine at Stanford University and earned her MD–PhD in 2004.[3] She completed her internship at Stanford before leaving to join Harvard Medical School as a medical resident in neurology. Monje worked in the Brigham and Women's Hospital as well as the Massachusetts General Hospital. She completed a fellowship at the Stanford University School of Medicine, where she was mentored by Philip A. Beachy, and was board certified in neuro-oncology and neurological subspecialities in 2013.[2] During her clinical training in neural development, Monje had four children.[1]

Research and career

Her research considers the molecular mechanisms for neurodevelopment and neuroplasticity.[4] She looks at how the neural circuits responsible for cognitive and motor functions are developed, and how the microenvironment of a tumour impacts the transition of precursor cells to diseased cells.[5] She studies brainstem tumours as a paradigm for paediatric gliogenesis.[6] Monje works at Stanford University, where she has developed new treatments for brain cancer since 2011.[7] She has extensively investigated Diffuse Intrinsic Pontine Glioma (DIPG), a cancer for which it is difficult to identify effective chemotherapy and impossible to remove surgically, as the tumour grows in the brainstem.[8] In 2009 she grew the first laboratory cultures of DIPG from deceased donors, which allowed her and her team to monitor the cell's growth and test chemotherapy agents.[9] The tumour tissue resources developed in Monje's laboratory are shared with researchers all around the world.[8] She also uses mouse models to test possible therapies.

Monje is leading a Phase 1 clinical trial of panobinostat, a drug which slows the growth of DIPG and has been shown to increase survival rates in mice. She has also engineered immune cells including the chimeric antigen receptor T (CAR-T) cells to eradicate brain tumours.[10] This work involved screening DIPG tumour cultures for surface molecules that could be targets for CAR-T cells. Monje found that GD2 is present on the surface of 80% of DIPG tumours. Over expression of the sugar molecule is caused by the H3K27M mutation and drives the growth of tumour. Crystal Mackall developed CAR-T cells that attack the GD2, killing cultured DIPG cells which carry the H3K27M mutation.[10] Monje's engineered cells can cross the blood–brain barrier, and have been shown to greatly reduce the number of cancer cells in mice.[10]

She was board certified by the American Board of Psychiatry and Neurology in Neurology in 2018. She was recognised by State senator Jerry Hill with a Certificate of Recognition in June 2019.[8] The campaigning and research of Monje resulted in the United States renaming May 17 as Paediatric Brain Cancer Awareness Day.[8] Her research is supported by family members of children who have suffered from DIPG.[2][11] Monje serves on the advisory board of Abbie's Army, a non-profit that fights for a cure for DIPG.[12]

She is a recipient of the 2019 Presidential Early Career Award for Scientists and Engineers.[13]

Awards and honors

  • 2019 Presidential Early Career Award for Scientists and Engineers (PECASE)[14]
  • 2017 Neuro-Oncology Investigator Award, American Academy of Neurology [15]


Selected publications

Scholia has an author profile for Michelle Monje.
  • Monje, Michelle (2003). "Inflammatory blockade restores adult hippocampal neurogenesis". Science. 302 (5651): 1760–1765. Bibcode:2003Sci...302.1760M. doi:10.1126/science.1088417. PMID 14615545. S2CID 36806485.
  • Monje, Michelle (2002). "Irradiation induces neural precursor-cell dysfunction". Nature Medicine. 8 (9): 955–962. doi:10.1038/nm749. PMID 12161748. S2CID 10347561.
  • Monje, Michelle (April 2003). "Radiation injury and neurogenesis". Current Opinion in Neurology. 16 (2): 129–134. doi:10.1097/00019052-200304000-00002. PMID 12644738.
  • Monje M.  (July 2018). "Myelin plasticity and nervous system function". Annu Rev Neurosci. 8 (41):61-76. Annu Rev Neurosci. doi: 10.1146/annurev-neuro-080317-061853.[16]

Personal life

Monje is married to neuroscientist Karl Deisseroth, with whom she has four children.

References

  1. ^ a b "Curing The Uncurable: Meet Dr. Michelle Monje, the researcher powering cures for deadly brain tumors". Alex's Lemonade Stand Foundation for Childhood Cancer. 2018-07-18. Retrieved 2019-08-01.
  2. ^ a b c d e Printz, Carrie (2019). "First person profile: Michelle Monje, MD, PhD". Cancer. 125 (9): 1397–1398. doi:10.1002/cncr.32132. ISSN 1097-0142. PMID 30990897.
  3. ^ "default - Stanford Children's Health". www.stanfordchildrens.org. Retrieved 2019-08-01.
  4. ^ "SFARI | Michelle Monje". SFARI. 2019-01-18. Retrieved 2019-08-01.
  5. ^ "2019 Keynote lecture: Michelle Monje | Canadian Association for Neuroscience". Retrieved 2019-08-01.
  6. ^ "Monje". www.soc-neuro-onc.org. Retrieved 2019-08-01.
  7. ^ Michelle Monje: New therapies for brain cancer, retrieved 2019-08-01
  8. ^ a b c d "Moonshot4Kids" at Monje Lab: DIPG families advocate for increased pediatric cancer research funds". Healthier, Happy Lives Blog. 2019-06-07. Retrieved 2019-08-01.
  9. ^ "DIPG Research fundraiser". my.supportlpch.org. Retrieved 2019-08-01.
  10. ^ a b c "Altered immune cells clear childhood brain tumor in mice". News Center. Retrieved 2019-08-01.
  11. ^ "Mom's fundraising helps advance research into deadly brain tumor". News Center. Retrieved 2019-08-01.
  12. ^ "Advisory Board - Abbie's Army". www.abbiesarmy.co.uk. Retrieved 2019-08-01.
  13. ^ "President Donald J. Trump Announces Recipients of the Presidential Early Career Award for Scientists and Engineers". www.whitehouse.gov. 2019-07-02. Retrieved 2019-08-03.
  14. ^ News, Stanford. "Twelve from Stanford honored with the Presidential Early Career Award for Scientists and Engineers | The Dish". news.stanford.edu. Retrieved 2020-05-27. {{cite web}}: |last= has generic name (help)
  15. ^ "American Academy of Neurology Announces 2017 Scientific Research Award Winners". www.aan.com. Retrieved 2020-06-11.
  16. ^ "Monje Lab Selected Publications". Monje Lab. Retrieved 2020-03-05.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Michelle_Monje&oldid=999256057"